William E. Haley, M.D., is a nephrologist with more than 35 years of both clinical and research experience specializing in clinical nephrology and hypertension. Dr. Haley's research is focused on urinary stone disease (urolithiasis), hypertension treatment and improving chronic kidney disease (CKD) care, and he is an expert in the prevention and treatment of urolithiasis.
Dr. Haley and colleagues engage in cutting-edge research in the genetics and epidemiology of urolithiasis and in improvements in diagnostic imaging. They recently reported that specific mutations of the HOGA1 gene observed in patients with type III primary hyperoxaluria are also observed in people who form idiopathic calcium oxalate stones.
This observation led to the hypothesis that mutations in monogenic forms of nephrolithiasis may be a predisposing factor for idiopathic calcium oxalate stone formation. With funding from the National Institutes of Health (NIH), Dr. Haley is now investigating this in collaboration with co-principal investigator Alexander S. Parker, Ph.D., and Dawn S. Milliner, M.D.
Dr. Haley also serves as site principal investigator for other NIH-supported research on the epidemiology of kidney stones and CKD and a diagnostic study of utility of dual energy CT technology to accurately determine kidney stone composition. He collaborates with David S. Goldfarb, M.D., Peter C. Harris, Ph.D., John C. Lieske, M.D., Cynthia H. McCollough, Ph.D., and Andrew D. Rule, M.D., on various studies on the etiology, prognosis, epidemiology, diagnosis and treatment of urolithiasis.
Dr. Haley serves on the executive committee of the O'Brien Urology Research Center at Mayo Clinic's campus in Rochester, Minnesota, and also serves on the Rare Kidney Stone Consortium, of which Mayo Clinic's campus in Jacksonville, Florida, is a coordinating center.
- Genetics of urolithiasis. Building on their current research, Dr. Haley and colleagues are developing a study to explore the genetics of and relationship between calcium, phosphorus, and vitamin D homeostasis and kidney stone disease.
- Clinical practice guidelines for CKD. Over the course of two decades of work with guidelines and performance measures, one problem stood out in terms of impact of these efforts: the lack of coordination and cooperation between specialists and primary care practitioners and the accompanying fragmentation of care. In response, Dr. Haley developed a toolkit — sponsored by the Renal Physicians Association — for the care of patients with CKD and for enhancing coordination between nephrologists and primary care.
Diagnosis and treatment of kidney stone disease. Dr. Haley and collaborators were the first to describe the utility of dual energy CT imaging in patients requiring ureteral stents, and were the first to describe important issues in image interpretation and artifacts. They have also addressed the clinical applicability of dual energy CT in kidney stone disease, along with concerns about radiation exposure.
This work, together with his research on the genetics of kidney stone disease, has nationally and internationally established Mayo Clinic's campus in Jacksonville, Florida, as making significant contributions in kidney stone disease research.
Significance to patient care
Dr. Haley's overall research goal is to contribute to the development of better methods to successfully prevent and detect kidney disease, and to provide patients who have kidney disease with options for effective treatment or disease management.
- Co-chair, Chronic Kidney Disease Measures Workgroup, American Medical Association, 2005-present
- Chair, Public Policy and Socioeconomic Issues Workgroup, Kidney Disease Outcomes Quality Initiative, National Kidney Foundation, 2000-present
- Top teacher award, Division of Nephrology and Hypertension, Mayo Clinic, 2010, 2009, 2006, 2005, 2004
- Distinguished Nephrology Service Award, Renal Physicians Association, 2006